In 2014, a clinical trial conducted by Harvard Medical School and Johns Hopkins University at Massachusetts General Children's Hospital (NCT:01474993) found that sulforaphane is helpful to improve social interaction, abnormal behavior and language communication in autism patients（https://pubmed.ncbi.nlm.nih.gov/25313065/）. In 2018, the University of California published the results of a clinical trial in which sulforaphane increased conversation and eye contact, reduced meaningless voice, calmer, less repetitive and self injurious behaviors in the University of California published the results of a clinical trial in which sulforaphane increased conversation, reduced meaningless voice, increased eye contact, calmer, less repetitive and self injurious behaviors in autistic patients patients （https://pubmed.ncbi.nlm.nih.gov/29854372/）.

In 2015, animal and human studies at Chiba University Hospital in Japan found that dietary intake of glucoraphanin in adolescence can prevent and treat the cognitive impairment of schizophrenia, and prevent high-risk groups from transforming into schizophrenia in adulthood （https://pubmed.ncbi.nlm.nih.gov/26107664/）.

In 2016 and 2017, animal studies at Chiba University showed that  the intake of sulforaphane in adolescents and young adults can prevent depression-like behavior following chronic social frustration stress or bacterial endotoxin LPS administration, indicating that sulforaphane has a preventive effect on depression （https://pubmed.ncbi.nlm.nih.gov/27470577/；https://pubmed.ncbi.nlm.nih.gov/27833054/）.

Figure: Depression and other common mental disorders: global health estimates by WHO (2017)